TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) shares dropped 1.9% during trading on Friday . The stock traded as low as $1.58 and last traded at $1.58. Approximately 2,542 shares traded hands during trading, a decline of 74% from the average daily volume of 9,615 shares. The stock had previously closed at $1.61.
TriSalus Life Sciences Stock Performance
The company’s fifty day moving average is $1.84 and its 200-day moving average is $1.54.
TriSalus Life Sciences Company Profile
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Articles
- Five stocks we like better than TriSalus Life Sciences
- Why is the Ex-Dividend Date Significant to Investors?
- Tesla: 2 Reasons to Love Musk’s $1B Buy, 1 Reason to Be Bearish
- What is a buyback in stocks? A comprehensive guide for investors
- Azure Leads While AI Excitement Fuels Microsoft Stock
- Bank Stocks – Best Bank Stocks to Invest In
- Darden Restaurants: A Textbook Buy-the-Dip Opportunity
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
